FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

PERJETA

Drug and asset intelligence for PERJETA with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Roche →

Mechanism of action

HER2 Inhibitor

Recent signals(2)

RegulatoryJuly 28, 2026

FDA Accepts Supplement for PERJETA (Pertuzumab) by Genentech

The FDA has accepted a supplemental Biologics License Application for PERJETA (pertuzumab) from Genentech.

RegulatoryJuly 5, 2026

FDA Accepts Supplemental Application for PERJETA by Genentech

The FDA has accepted a supplemental application for PERJETA (pertuzumab) from Genentech.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Roche — PERJETA

July 5, 2026 · N/A

Indications

HER2-positive Breast Cancer →

Therapeutic areas

HER2 Inhibitor →

HER2-positive Breast Cancer →

Oncology →

Oncology · HER2 Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.